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Selenium Supplementation and the Effects on 
Reproductive Outcomes, Biomarkers of Inflammation, 
and Oxidative Stress in Women with Polycystic Ovary 
Syndrome
ROS  Reactive oxygen species 
RDA  Recommended Dietary Allowances 
RA  Rheumatoid arthritis 
SIRS	 		Systemic	inflammatory	response	
 syndrome 
SFA  Saturated fatty acid 
TAC  Total antioxidant capacity 
TAS  Total antioxidant status 
T2DM  Type 2 diabetes mellitus 
TNF-α	 	Tumor	necrosis	factor	alpha	
TDF	 	Total	dietary	fiber	
tT  Total testosterone
Introduction
▼
Polycystic ovary syndrome (PCOS) is a common 
endocrine	and	metabolic	aberration	[1],	affecting	
5–10  % of women of childbearing age in world-
wide [2]. Previous studies have shown that PCOS 
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Abstract
▼
Selenium	supplementation	could	be	effective	on	
reproductive	outcomes,	biomarkers	of	inflamma-
tion, and oxidative stress among women with 
polycystic ovary syndrome (PCOS). The aim of 
the	 study	was	 to	 determine	 the	 effects	 of	 sele-
nium supplementation on reproductive out-
comes,	 biomarkers	 of	 inflammation,	 and	
oxidative stress in PCOS patients. The present 
randomized	 double-blind,	 placebo-controlled	
trial was conducted on 64 women aged 18–40 
years	old	with	PCOS	at	the	clinic	affiliated	to	Ard-
abil University of Medical Sciences, Ardabil, Iran. 
The participants were randomly assigned to 2 
groups	 receiving	 either	 200	μg	 selenium	 daily	
(n	=	32)	or	placebo	(n	=	32)	for	8	weeks.	Hormonal	
profiles,	biomarkers	of	inflammation,	and	oxida-
tive stress were measured and compared both 
before and after the treatment. After 8 weeks of 
intervention, pregnancy rate in the selenium 
group was higher than in the placebo group: 18.8 
(6/32) vs. 3.1 % (1/32), p = 0.04. In addition, alope-
cia (40.6 vs. 9.4 %, p = 0.004) and acne (46.9 vs. 
12.5  %, p = 0.003) decreased following the con-
sumption of selenium supplements compared 
with placebo. Additionally, patients who received 
selenium	supplements	had	significantly	decreased	
serum	 dehydroepiandrosterone	 (DHEA)	 levels	
(p	=	0.02),	hirsutism	(modified	Ferriman–Gallwey	
scores) (p < 0.001), serum high sensitivity C-reac-
tive protein (hs-CRP) (p = 0.02), and plasma 
malondialdehyde (MDA) levels (p = 0.01) compared 
with	placebo.	We	did	not	observe	any	significant	
effects	of	 taking	 selenium	supplements	on	other	
hormonal	 profiles,	 nitric	 oxide	 (NO),	 and	 other	
 biomarkers of oxidative stress. Taken together, 
selenium supplementation for 8 weeks among 
PCOS	women	had	beneficial	effects	on	reproduc-
tive	outcomes,	DHEA,	hs-CRP,	and	MDA	levels.
Supporting Information for this article is available 
online at http://www.thieme-connect.de/products.
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is the most prevalent cause of female infertility, which is charac-
terized	by	ovarian	hyperandrogenism	and	chronic	anovulation	
[3]. In addition, due to increased production of free radicals and 
reactive oxygen species (ROS) [4], elevated circulating protein 
carbonyls,	tumor	necrosis	factor-α	(TNF-α),	and	decreased	insu-
lin signaling [5, 6], it is associated with increased biomarkers of 
inflammation	and	oxidative	stress.	Increased	inflammatory	fac-
tors and biomarkers of oxidative stress among patients with 
PCOS may predict the development of cardiovascular disease 
(CVD) and type 2 diabetes mellitus (T2DM) [7–9].
Recent	 studies	 have	 reported	 that	 the	 use	 of	 insulin-sensitiz-
ing	drugs	 including	metformin,	rosiglitazone,	and	pioglitazone	
improves ovulation by improving clinical and biochemical fea-
tures of patients diagnosed with PCOS [10]. Selenium is an 
essential trace element, which has importance to human biol-
ogy and health. More recently, evidence has also been presented 
that	 selenium	 may	 affect	 several	 reproductive	 and	 obstetric	
complications including male and female infertility [11]. Fur-
thermore,	 current	 data	 supports	 the	 beneficial	 effect	 of	 sele-
nium	supplementation	on	metabolic	profiles	and	biomarkers	of	
oxidative stress among patients with PCOS [12, 13]. Valenta et al. 
[14] demonstrated that high-dose selenium supplementation 
for	 14	 days	 (1	000	μg	 on	 day	 1	 and	 500	μg/day	 on	 days	 2–14)	
decreased	plasma	CRP	levels	in	patients	with	systemic	inflam-
matory response syndrome (SIRS)/sepsis. Increased erythrocyte 
and plasma total antioxidant status (TAS), reduced glutathione 
(GSH),	and	glutathione	peroxidase	(GSH-Px)	were	also	seen	fol-
lowing the intake selenium supplements in patients with epi-
lepsy	 and	 refractory	 epilepsy	 [15].	 However,	 no	 significant	
change in malondialdehyde (MDA) concentrations was seen 
after the consumption of selenium supplements in rats [16].
Beneficial	 effects	 of	 selenium	 supplementation	 on	 improved	
reproductive	outcomes,	biomarkers	of	inflammation,	and	oxida-
tive	 stress	might	 be	 attributed	 to	 its	 inhibitory	 effect	 on	 aug-
mentation	 of	 proinflammatory	 cytokines	 and	 reactive	 oxygen	
species/reactive nitrogen species [17, 18]. Borderline selenium 
status is high among healthy Iranian women. Rafraf et al. [19] 
reported that 69 women have serum selenium concentrations 
under	80	μg/l.	Although	there	is	no	specific	data	on	mean	daily	
intake of selenium in Iranian women with PCOS, the mean of 
selenium consumption among postmenopausal women was sig-
nificantly	less	than	the	Recommended	Dietary	Allowances	(RDA)	
[20].	Considering	these	points,	we	hypothesized	that	selenium	
supplementation	might	affect	reproductive	outcomes,	biomark-
ers	of	inflammation,	and	oxidative	stress	in	patients	with	PCOS.	
We are aware of no such study among PCOS women. This study 
was	thus	aimed	to	investigate	the	effect	of	selenium	supplemen-
tation	on	reproductive	outcomes,	biomarkers	of	 inflammation,	
and oxidative stress of PCOS women.
Subjects and Methods
▼
Participants
Sixty four women with PCOS from October 2014 to December 
2014 were included in the patients attending the outpatient 
clinic of the Infertility Research Center of Ardabil Medical Uni-
versity. The current study was approved by the Institutional 
Review Board at Ardabil University of Medical Sciences (AUMS). 
Informed written consent was obtained from all participants. 
This study was done based on the guidelines laid down in the 
Declaration	of	Helsinki.	The	 trial	was	 registered	 in	 the	 Iranian	
website (www.irct.ir) for registration of clinical trials (IRCT 
code: IRCT201412295623N33). The diagnosis of PCOS was 
according	 to	 European	 Society	 for	 Human	 Reproduction	 and	
Embryology/American	 Society	 for	 Reproductive	 Medicine	
guidelines (Rotterdam criteria, 2003), as including at least 2 of 
the following 3 criteria: 1) oligo- and/or anovulation as the pres-
ence of chronic amenorrhea or a menstrual cycle length of less 
than 21 days or more than 35 days, or more than 4 days variation 
between cycles; 2) clinical or biochemical signs of hyperandro-
genism; and 3) polycystic ovary morphology shown on ultra-
sound	examination,	defined	as	12	or	more	small	 follicles	 [21].	
Our inclusion criteria were age between 18 and 40 years with 
PCOS according to Rotterdam criteria. In the current study, we 
excluded patients who had elevated levels of prolactin, thyroid 
disorder, or T2DM and congenital adrenal hyperplasia. In addi-
tion, all PCOS women had normal baseline renal function tests, 
bilirubin, and aminotransferases. During the last 3 months 
before the intervention, none of the study patients used any 
form of oral contraceptives (OCPs), other steroid hormones, or 
any	 other	 treatments	 likely	 to	 affect	 ovarian	 function,	 insulin	
sensitivity,	 or	 inflammatory	 factors,	 biomarkers	 of	 oxidative	
stress as well as nutritional supplements.
Study design
At	the	first	trial	and	after	stratification	for	pre-supplementation	
BMI	(<	25	and	≥	25	kg/m2)	and	age	(<	30	and	≥	30	years),	patients	
with	 PCOS	 were	 randomly	 divided	 into	 2	 groups.	 Group	 1	
received	200	μg	daily	selenium	tablet	as	selenium	yeast	(n	=	32)	
and group 2 received the placebo (n = 32) for 8 weeks. Selenium 
supplements and its placebos (cellulose) were manufactured by 
Nature Made Pharmaceutical Company (California, USA) and 
Barij	 Essence	Pharmaceutical	 Company	 (Kashan,	 Iran),	 respec-
tively. Supplements and placebos were in the same form of 
package and the patients and researcher were not conscious of 
the content of the pack until the end of trial. In addition, all 
patients with PCOS took metformin at the initial dose of 500 mg, 
which	 was	 elevated	 in	 a	 stepwise	 manner	 during	 the	 first	 3	
weeks	to	incorporate	the	side	effects	until	the	patients	were	tak-
ing	a	total	of	1	500	mg/day.	Patient	allocation	and	block	size	were	
obtained using random number tables. At the time of randomi-
zation,	sequentially	numbered,	sealed	envelopes	were	opened.	
Allocation to study group was concealed until the main analyses 
were	completed.	The	randomized	allocation	sequence,	enrolling	
participants, and assigning participants to interventions were 
done by a trained midwife at gynecology clinic. At the beginning 
study,	 the	 subjects	were	 requested	 to	 keep	 their	 usual	 diet	 and	
level of physical activity throughout the study period as well as not 
to	receive	any	anti-inflammatory	medications,	supplements,	and	
other	medications	that	might	affect	their	reproductive	physiology	
during the 8-week intervention. The use of selenium supplements 
and placebos throughout the study was checked through asking 
participants to bring the medication containers. To increase the 
compliance, all patients were receiving short messages on their 
cell phones to take the supplements each day. All participants pro-
vided 3 dietary records (1 weekend day and 2 weekdays) and 3 
physical activity records at week 2, 4, and 6 of intervention to 
make sure that they maintained their usual diet and physical 
activity during intervention. The dietary records were based on 
estimated values in household measurements. In the current 
study, we used Nutritionist IV software (First Databank, San Bruno, 
CA, USA) adjusted for Iranian foods to take macro and micronutri-
ents intakes of patients according to 3-day food  diaries.
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Assessment of variables
All participants were evaluated at baseline study on the third 
day of a spontaneous or progesterone-induced menstrual cycle. 
Anthropometric assessments included determinations of height, 
weight	(Seca,	Hamburg,	Germany),	and	body	mass	index	(BMI).	
Clinical assessments included determinations of hirsutism using 
modified	Ferriman-Gallwey	scores	[22],	of	acne	score	[23],	and	
of alopecia based on assessment guidelines collated by Olsen et 
al. [24]. Acne was marked by a 4-point scale: 0, no acne; 1, minor 
acne on face; 2, moderate acne on face only; and 3, severe acne, 
face and back or chest. In case of missed menstrual period, we 
checked	 β-human	 chorionic	 gonadotropin	 (β-HCG)	 to	 detect	
pregnancy	a	week	after	the	missed	period.	If	β-HCG	levels	were	
higher than 25 (by the Vidas method), the patient was pregnant 
and medications discontinued. Fasting blood samples (10 ml) 
were collected before and 8 weeks after of the intervention at 
Ardabil reference laboratory in an early morning after an over-
night fast. Blood was collected in 2 separate tubes: 1) one with-
out	 EDTA	 to	 separate	 the	 serum,	 in	 order	 to	 quantify	 serum	
prolactin,	follicular-stimulating	hormone	(FSH)	and	luteinizing	
hormone	 (LH),	 free	 testosterone,	 dehydroepiandrosterone	
(DHEA)	 and	high	 sensitivity	C-reactive	protein	 (hs-CRP)	 levels	
and	2)	another	one	containing	EDTA	to	examine	plasma	nitric	
oxide (NO) and biomarkers of oxidative stress. Blood samples 
were	immediately	centrifuged	(Hettich,	78	532	Tuttlingen,	Ger-
many) at 3 500 rpm for 10 min to separate the serum. The sam-
ples	 were	 then	 stored	 at	 	−	70	°C	 until	 being	 analyzed	 at	 the	
AUMS reference laboratory. Commercial kits were used to meas-
ure	serum	prolactin,	FSH	and	LH	concentrations	 (Pars	Azmun,	
Tehran,	 Iran).	 All	 inter-	 and	 intra-assay	CVs	 for	 prolactin,	 FSH	
and	LH	measurements	were	less	than	7	%.	Serum	free	testoster-
one,	DHEA,	and	17-OH	progesterone	concentrations	were	deter-
mined by using commercial kits (Monobind, CA, USA). Serum 
hs-CRP	was	quantified	using	an	ELISA	kit	(LDN,	Nordhorn,	Ger-
many) with intra- and interassay CVs of 2.9 and 4.8 %, respec-
tively. The plasma NO concentration was determined by the 
Griess	method	[25].	Plasma	total	antioxidant	capacity	(TAC)	was	
assessed by the use of the ferric reducing antioxidant power 
(FRAP)	method	developed	by	Benzie	and	Strain	[26].	Plasma	GSH	
was examined using the method of Beutler et al. [27]. The 
plasma MDA levels were determined by the thiobarbituric acid 
reactive substance spectrophotometric test [28]. CVs for plasma 
TAC,	GSH	and	MDA	were	1.1,	2.8,	and	3.7	%,	respectively.
Statistical methods
We	 used	 the	 Kolmogrov-Smirnov	 test	 to	 examine	 if	 variables	
were normally distributed. Intention-to-treat (ITT) analysis of 
the primary study end-point was performed for all the randomly 
assigned participants. Missing data from dropped out partici-
pants were imputed using the method of “Last Observation Car-
ried	Forward	(LOCF)”.	The	Pearson	chi-square	test	was	used	to	
compare categorical variables. Independent sample Student’s 
t-test	was	used	 to	detect	differences	 in	general	 characteristics	
and dietary intake between the 2 groups. To determine the 
effects	 of	 selenium	 supplementation	 on	 hormonal	 profiles,	
inflammatory	 factors	 and	 biomarkers	 of	 oxidative	 stress,	 one-
way repeated-measures ANOVA was used to evaluate the 
between-group changes in variables during the study. In this 
analysis, the treatment was regarded as between-subject factor 
and time with 2 time-points (baseline and 8 weeks after of the 
intervention) was considered as within-subject factor. To assess 
if the magnitude of the change in dependent variables depended 
on the baseline age and BMI, we controlled all analyses for base-
line values of age and BMI to avoid potential bias. These analyses 
were also done using one-way repeated measures ANOVA. A 
p-value	<	0.05	was	considered	statistically	significant.	All	statis-
tical analyses were done using the Statistical Package for Social 
Science version 17 (SPSS Inc., Chicago, IL, USA). In the current 
study, the primary endpoint variables were biomarkers of oxida-
tive	stress	including	plasma	TAC,	GSH,	and	MDA	levels.	To	calcu-
late	the	sample	size,	we	used	the	standard	formula	suggested	for	
parallel	clinical	trials	by	considering	type	one	error	(α)	of	0.05	
and	type	2	error	(β)	of	0.20	(power	=	80	%).	Based	on	a	previous	
study	[29],	we	used	2.19	μmol/l	as	SD	and	2.80	μmol/l	as	the	dif-
ference in mean (d) of MDA levels as key variable. Based on this, 
we reached to 27 patients in each group. Assuming a dropout of 
5	patients	per	group,	the	final	sample	size	was	determined	to	be	
32 patients per group.
Results
▼
Baseline evaluations and dropouts
In the current study, 64 women with PCOS met the inclusion 
criteria based on Rotterdam criteria and were enrolled in the 
study. Among the individuals in the selenium group, 2 women 
[withdrawn due to personal reasons (n = 2)] and in the placebo 
group, 2 women [withdrawn due to personal reasons (n = 2)] did 
not	complete	the	trial.	However,	as	the	analysis	was	done	accord-
ing to ITT protocol, all 64 patients with PCOS were included in 
the end analysis. On the average, the rate of compliance in our 
study was high, such that  > 90 % of tablets were taken through-
out	the	study	in	both	groups.	No	side	effects	were	reported	fol-
lowing the administration of selenium supplements in patients 
with PCOS throughout the study.
General characteristics of study participants
Mean age (25.1 ± 4.5 vs. 25.4 ± 4.9 years, p = 0.85), baseline BMI 
(24.7 ± 3.5 vs. 25.3 ± 4.3 kg/m2, p = 0.53), and end-of-trial BMI 
(24.3 ± 3.5 vs. 25.1 ± 4.2 kg/m2,	 p	=	0.47)	 were	 not	 significantly	
different	between	selenium	and	placebo	groups.
Dietary intakes of study participants throughout the 
study
According to the 3-day dietary records taken throughout the 
intervention,	any	significant	change	was	not	seen	between	the	2	
groups in terms of dietary intakes of energy, carbohydrates, pro-
teins, fats, saturated fatty acids (SFAs), polyunsaturated fatty 
acids (PUFAs), monounsaturated fatty acids (MUFAs), choles-
terol,	 total	 dietary	 fiber	 (TDF),	 selenium,	magnesium,	manga-
nese,	vitamins	C	and	E	(data	not	shown).
Clinical outcomes
After 8 weeks of intervention, pregnancy rate in the selenium 
group was higher than in the placebo group: 18.8 (6/32) vs. 3.1 % 
(1/32), p = 0.04 (Table S1). In addition, alopecia (40.6 vs. 9.4 %, 
p = 0.004) and acne (46.9 vs. 12.5  %, p = 0.003) decreased follow-
ing the consumption of selenium supplements compared with 
placebo.
The effect of selenium supplementations on 
biochemical measurements
Patients	who	received	selenium	supplements	had	significantly	
decreased	 serum	 DHEA	 levels	 (p	=	0.02),	 hirsutism	 (p	<	0.001),	
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serum hs-CRP (p = 0.02), and plasma MDA levels (p = 0.01) com-
pared with placebo ( ●▶	 Table 1).	We	did	not	observe	any	signifi-
cant	effects	of	taking	selenium	supplements	on	other	hormonal	
profiles,	NO,	and	other	biomarkers	of	oxidative	stress.	We	con-
trolled	the	baseline	levels	in	the	analyses.	However,	after	adjust-
ment	no	significant	changes	in	our	findings	occurred,	except	for	
FSH	(p	=	0.03)	and	DHEA	levels	(p	=	0.12).
Adjusted changes in biochemical measurements
Additional	adjustments	for	age	and	baseline	BMI	did	not	affect	
our	findings,	except	for	FSH	(p	=	0.03)	and	DHEA	levels	(p	=	0.13)	
(Table S2).
A	summary	of	patient	flow	diagram	is	presented	in	Fig. S1.
Discussion
▼
We	revealed	for	the	first	time	that	selenium	supplementation	in	
PCOS	women	resulted	in	a	significant	increase	in	pregnancy	rate,	
a	 decreased	 reduction	 in	 alopecia,	 acne,	 DHEA,	 hirsutism,	 hs-
CRP and MDA levels. It must be considered that mean dietary 
plus supplemental selenium intake was lower in our study 
patients	than	upper	limits	(400	µg).	However,	data	on	the	effects	
of selenium supplementation on toxicity/teratogenicity even in 
subjects	with	high	dietary	 selenium	 intake	are	 conflicting.	 For	
instance, some of the subjects in Burk et al study [30] 
ingested	>800	μg	selenium/d	for	16	weeks.	However,	this	is	con-
siderably more than the Institute of Medicine’s tolerable upper 
level	of	400	μg/d [31], no signs of selenium toxicity in mentioned 
study were observed. In another study by Reid et al. [32] more 
subjects	on	3200	μg/day	have	 reported	symptoms	of	 selenium	
toxicity.
Women with PCOS are susceptible to infertility, hirsutism, 
increased	 inflammatory	 factors	 and	 increased	 biomarkers	 of	
oxidative stress [33]. Our study demonstrated that taking sele-
nium supplements for 8 weeks in women with PCOS resulted in 
a	significant	increase	in	pregnancy	rate,	a	significant	reduction	
in alopecia and acne compared with placebo. Data regarding 
favorable	 effects	 of	 selenium	 intake	 and	 female	 fertility	 are	
scarce. In line with our study, conception rate following the 
intake of 50 mg/ml selenium as barium selenate was higher than 
in the control ewes [34]. In addition, fertility has been improved 
by	supplemental	co-administration	of	vitamin	E	and	selenium	in	
cattle	 [35].	 Paszkowski	 et	 al.	 [36]	 reported	 that	 patients	with	
unexplained	 infertility	 had	 a	 significant	 decrease	 in	 follicular	
selenium concentrations compared with patients with tubal 
infertility. Furthermore, a recent study has shown lower levels of 
serum	 and	 follicular	 fluid	 selenium	 in	 women	 undergoing	 in	
vitro	 fertilization	 treatment	 compared	with	nonpregnant	 con-
trol	women	[37].	Edassery	et	al.	[38]	reported	that	women	with	
unexplained	infertility	or	premature	ovarian	failure	have	signifi-
cantly increased serum levels of the ovarian autoantibody pro-
tein,	 selenium	 binding	 protein-1.	 However,	 some	 researchers	
have not found association between herd selenium concentra-
tions and fertility parameters [39]. Previous studies have 
reported that selenium intake is associated with decreased bio-
markers of oxidative stress and insulin resistance in women with 
PCOS [12, 13]. Antioxidants are compounds that are capable of 
disposing or suppressing the formation of ROS, free radicals, and 
lipid	hydroperoxides	[40].	However,	no	study	has	directly	evalu-
ated	the	effects	of	oxidative	stress	on	fertility	in	women;	a	recent	
review	 has	 reported	 that	 antioxidants	 may	 influence	 female	
reproduction [41]. In addition, insulin resistance in patients with 
PCOS	 influences	 the	developmental	potential	 of	human	 imma-
ture oocytes, as indicated by impaired oocyte maturation, fewer 
fertilized	oocytes,	and	cleaved	embryos	[42,	43].
Results of the present study show that selenium supplementa-
tion	among	PCOS	women	decreased	serum	DHEA	levels	and	hir-
sutism,	 while	 did	 not	 affect	 other	 hormonal	 profiles.	 As	 this	
study	is	among	the	first	that	reports	the	effect	of	selenium	sup-
plementation	on	hormonal	profiles	among	women	with	PCOS,	
we	did	not	compare	findings	of	 the	current	study	with	others	
although few studies assessed the association between selenium 
levels	and	hormonal	profiles	in	women	with	PCOS.	For	instance,	
Coskun et al. [44] reported decreased plasma concentrations of 
selenium	and	a	negative	association	between	selenium	and	LH,	
total testosterone (tT) in PCOS women, indicating that selenium 
may play a role in the pathogenesis of PCOS related with hyper-
Table 1	 The	effect	of	selenium	supplementations	on	hormonal	status,	biomarkers	inflammation	and	oxidative	stress.
Placebo group (n = 32) Selenium group (n = 32) p * 
Week 0 Week 8 Change Week 0 Week 8 Change
Prolactin (mIU/l) 643.27 ± 376.31 546.11 ± 262.97 	−	97.15	±	443.26 697.01 ± 614.53 743.28 ± 585.41 46.26 ± 337.43 0.15
FSH (IU/l) 7.92 ± 2.85 8.40 ± 3.05 0.48 ± 2.55 6.39 ± 3.17 6.15 ± 3.38 	−	0.24	±	4.28 0.41
LH (IU/l) 13.67 ± 13.53 11.48 ± 7.72 	−	2.19	±	13.77 10.93 ± 8.21 10.60 ± 8.94 	−	0.33	±	10.21 0.54
Free testosterone 
(pg/ml)
3.24 ± 1.77 3.02 ± 1.66 	−	0.21	±	0.92 2.70 ± 1.51 2.41 ± 1.46 	−	0.28	±	1.15 0.78
DHEA	(μg/ml) 1.59 ± 0.72 1.56 ± 0.73 	−	0.02	±	0.41 2.01 ± 0.80 1.65 ± 0.85 † 	−	0.36	±	0.73 0.02
17-OH Progesterone 
(ng/ml)
2.00 ± 1.39 1.76 ± 1.28 	−	0.23	±	1.68 2.39 ± 2.01 1.92 ± 1.82 	−	0.46	±	2.56 0.66
mF-G scores 8.34 ± 6.30 8.12 ± 6.24 	−	0.21	±	0.83 12.46 ± 7.21 10.12 ± 5.45 † 	−	2.34	±	2.57  < 0.001
hs-CRP (ng/ml) 2 572.26 ± 2 506.08 2 765.81 ± 2 372.19 193.54 ± 1117.45 2 184.06 ± 2 693.84 1 472.70 ± 1 444.43 † 	−	711.35	±	1959.37 0.02
NO	(μmol/l) 57.15 ± 17.09 57.22 ± 16.98 0.07 ± 23.38 46.91 ± 7.59 50.76 ± 14.75 3.85 ± 13.37 0.43
TAC (mmol/l) 696.45 ± 137.43 692.13 ± 138.74 	−	4.32	±	200.88 823.14 ± 195.00 803.60 ± 147.74 	−	19.54	±	135.00 0.72
GSH	(μmol/l) 437.30 ± 107.12 472.35 ± 148.66 35.05 ± 168.55 476.64 ± 122.77 459.92 ± 120.73 	−	16.72	±	132.53 0.17
MDA	(μmol/l) 4.40 ± 2.71 5.8 ± 3.03† 1.40 ± 3.11 4.95 ± 1.25 4.81 ± 1.36 	−	0.13	±	1.03 0.01
All values are means ± SDs
 * Obtained from repeated measures ANOVA test (time × group interaction)
DHEA:	Dehydroepiandrosterone;	FSH:	Follicle-stimulating	hormone;	GSH:	Glutathione;	Hs-CRP:	High	sensitivity	C-reactive	protein;	LH:	Luteinizing	hormone;	mF-G:	Modified	
Ferriman-Gallwey; MDA: Malondialdehyde; NO: Nitric oxide; TAC: Total antioxidant capacity
†	Significant	difference	with	baseline	study
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androgenism. Selenium supplementation may result in decreased 
serum	DHEA	levels	and	hirsutism	through	improved	markers	of	
insulin metabolism [13] and decreased oxidative stress [12]. 
Previous studies have demonstrated that a positive association 
between hyperandrogenism, hyperinsulinemia, and insulin 
resistance in females with elevated androgen levels due to PCOS 
[45, 46]. In addition, oxidative stress is directly correlated with 
both insulin resistance and hyperandrogenism, which in turn 
contribute to endocrine and biochemical alterations in women 
with	functional	ovarian	hyperandrogenism	(FOH)	[47].
The present study revealed that taking selenium supplements in 
PCOS patients for 8 weeks was associated with decreased serum 
hs-CRP	levels,	but	did	not	affect	plasma	NO	concentrations.	Sup-
porting with our study, administration of selen plus supple-
ments	 contained	 50	μg	 selenium,	 8	mg	 zinc,	 400	μg	 vitamin	A,	
125	mg	vitamin	C,	and	40	mg	vitamin	E	daily	has	reduced	hs-CRP	
concentrations among rheumatoid arthritis (RA) for 12 weeks 
[48]. In addition, high-dose selenium supplementation for 14 
days	(1	000	μg	on	day	1	and	500	μg/day	on	days	2–14)	has	led	to	
a	significant	decrease	in	plasma	CRP	levels	in	patients	with	SIRS/
sepsis	 [14].	 Unlike,	 no	 significant	 effect	 on	 hs-CRP	 levels	was	
observed	after	intake	of	cereal	biscuit	with	selenized	onion,	cur-
cuma, and green tea for 2 months among healthy adults [49]. 
Similar	 finding	was	 also	 seen	 in	 centrally	 obese	women	who	
consumed	 200	μg	 selenium	 supplements	 for	 6	 weeks	 [50].	
Increased	 inflammatory	 factors	 in	 patients	 with	 PCOS	 render	
them at a potential increased risk for the development of athero-
sclerosis, T2DM, cancer, infertility, and other comorbidities [51]. 
Selenium intake may decrease serum hs-CRP levels through 
inhibiting the activation of NF-kappa B by modulating selenopro-
tein genes expression [52] and increasing selenoprotein biosyn-
thesis which in turn results in suppressed CRP production [53].
We found that selenium supplementation among women with 
PCOS	has	resulted	in	a	significant	reduction	in	plasma	MDA	lev-
els,	but	it	could	not	affect	plasma	TAC	and	GSH	levels.	Similarly,	
Salehi	et	al.	[54]	demonstrated	a	significant	decrease	in	MDA	lev-
els	after	administration	of	200	μg	selenium	supplements	per	day	
for 12 weeks among hemodialysis patients. Furthermore, vita-
min	E-plus-selenium	combination	decreased	MDA	concentrations	
in	 streptozotocin-induced	 diabetic	 rats	 [55].	 Supplementation	
with	200	μg	selenium	per	day	for	3	weeks	did	not	influence	bio-
markers	of	oxidative	stress	including	TAS	and	GSH	levels	among	
overweight	 adults	 [56].	 However,	 few	 researchers	 did	 not	
observe	such	effects	of	selenium	supplementation	on	MDA	lev-
els.	For	instance,	any	significant	change	in	MDA	levels	was	not	
observed after taking selenium supplements in rats [16]. Previ-
ous studies have shown that oxidative stress in female reproduc-
tion is associated with polycystic ovarian syndrome and 
endometriosis [57]. Needless to say, these pathologies negatively 
influence	 pregnancy	 rates	 and	 IVF	 outcomes.	 Selenium	 is	 an	
essential	 component	 of	 the	 erythrocyte	 GSH-Px	 system	 [58],	
which functions as part of an antioxidant defense to protect 
polyunsaturated	 fatty	acids,	 the	damaging	effects	of	 free	 radi-
cals, and lipid hydroperoxides such as MDA [59]. In addition, 
selenium might decrease hydroperoxides levels via inhibiting 
production	of	proinflammatory	cytokines	and	 reactive	oxygen	
species/reactive nitrogen species [17].
Taken together, selenium supplementation for 8 weeks among 
PCOS	women	 had	 beneficial	 effects	 on	 reproductive	 outcomes,	
DHEA,	hs-CRP	and	MDA	levels.
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